The present results that BRD2 exerted pro-hypertrophic effects in cardiomyocytes, apart from the previously reported BRD4, might help to explain the promising effect of pan-BETi in treatment of pathological cardiac hypertrophy, rather than specific inhibitor of a single BET member. This evidence concerns the gene DNER and cardiac hypertrophy.